Angiodynamics Inc (NASDAQ:ANGO) Sellers Decreased By 1.32% Their Shorts As Of May 16, 2018

May 16, 2018 - By Andrea Pope

AngioDynamics, Inc. (NASDAQ:ANGO) Corporate Logo

During 2017 Q4 the big money sentiment increased to 1.26. That’s change of 0.09, from 2017Q3’s 1.17. 14 investors sold all, 48 reduced holdings as AngioDynamics, Inc. ratio is positive. 56 rose holdings while 22 funds bought holdings. Funds hold 33.90 million shares thus 1.62% more from 2017Q3’s 33.36 million shares.
First Quadrant Ltd Partnership Ca has 0.01% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 32,659 shs. Systematic Financial Management Ltd Partnership stated it has 0.1% in AngioDynamics, Inc. (NASDAQ:ANGO). Axa has invested 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). Loomis Sayles And Limited Partnership holds 0% or 1,203 shs. Rothschild Asset reported 0.02% in AngioDynamics, Inc. (NASDAQ:ANGO). Lapides Asset Mngmt Lc reported 439,900 shs. Fny Managed Accounts owns 327 shs. D E Shaw holds 0% or 174,792 shs in its capital. 16,356 are held by Public Employees Retirement Association Of Colorado. Bnp Paribas Arbitrage Sa reported 0% stake. Fenimore Asset accumulated 594,490 shs. Barclays Public Ltd Company stated it has 9,084 shs or 0% of all its holdings. State Of New Jersey Common Pension Fund D reported 0% stake. Northern, Illinois-based fund reported 1.20M shs. California Pub Employees Retirement System invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO).

It was reported a decrease on Angiodynamics Inc (NASDAQ:ANGO)’s shorted shares with 1.32%. FINRA announced shorted shares of ANGO’s total 1.89 million shares. Previously was reported down change of 1.32% from 1.92 million shares. Angiodynamics Inc (NASDAQ:ANGO) has 164,600 shares average volume. It’ll cost 12 days for ANGO to restore its previous position. Float short on Angiodynamics Inc is 5.21%.

ANGO is reaching $19.93 during the last trading session, after increased 1.01%.AngioDynamics, Inc. has volume of 56,197 shares. Since May 16, 2017 ANGO has declined 2.41% and is downtrending. ANGO underperformed the S&P500 by 13.96%.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally.The firm is worth $733.51 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.553.61 is the P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

In total 3 analysts cover Angiodynamics (NASDAQ:ANGO). “Buy” rating has 1, “Sell” are 0, while 2 are “Hold”. 33% are bullish. 5 are the (NASDAQ:ANGO)’s analyst reports since January 5, 2018 according to StockzIntelligence Inc. The company rating was maintained by Canaccord Genuity on Monday, April 2. On Friday, January 5 the rating was downgraded by Craig Hallum to “Hold”. On Thursday, January 4 the stock has “Hold” rating by Canaccord Genuity. On Tuesday, April 3 the stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Outperform” rating by Raymond James. On Thursday, March 29 the stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Hold” rating by Canaccord Genuity.

AngioDynamics, Inc. (NASDAQ:ANGO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.